XTACY Therapeutics Provides Bi-Weekly MCTO Status Update

Vancouver, February, 13, 2024  – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (the “Company”) is providing a bi-weekly default status update in accordance with National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”)

In a press release dated January 30, 2024, the Company announced (theDefault Announcement”) that itsubmitted an application to the British Columbia Securities Commission (the “BCSC”), the Company’sprincipal regulator, for a management cease trade order (“MCTO”) in connection with the Company’sdelay in filing its audited annual financial statements for the year ended September 30, 2023, and themanagement’s discussion and analysis and related CEO and CFO certificates for the period (collectively, theRequired Documents”) which were required to be filed on or before January 29, 2024.

The MCTO was issued by the BCSC on January 30, 2024. It prevents the Company’s President and ChiefFinancial Officer from trading in the Company’s securities but does not affect the ability of othershareholders, including the public, to trade in the securities of the Company.

The MCTO remains in effect until the Company files the Required Documents and the BCSC’s ExecutiveDirector has revoked the MCTO. The Company anticipates that it will file the Required Documents in a short time. The Company confirms that since the date of the Default Announcement, other than asdescribed above: (a) there has been no material change to the information set out in the DefaultAnnouncement that has not been generally disclosed; (b) there has been no failure by the Company infulfilling its stated intentions with respect to satisfying the provisions of the alternative informationguidelines set out in NP 12-203; (c) there has not been, nor is there anticipated to be, any specified defaultsubsequent to the default which is the subject of the Default Announcement; and (d) there is no othermaterial information concerning the affairs of the Company that has not been generally disclosed.

The Company confirms that it will continue to satisfy the provisions of the alternative informationguidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for solong as it remains delayed in filing the Required Documents.

About Xtacy Therapeutics

Xtacy Therapeutics Corp. is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.

For further information visit websites:  www.xtacytherapeutics.com

Or Contact Meris Kott CEO 604.484.0355 or email to i[email protected]

Further information about the Company is available on www.sedarplus.ca. under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.